CATALYST PHARMACEUTICALS, INC. 10-Q Filing

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Marke

Filing Documents

• cprx-20250930.htm (10-Q) — 2544KB
• cprx-ex31_1.htm (EX-31.1) — 14KB
• cprx-ex31_2.htm (EX-31.2) — 14KB
• cprx-ex32_1.htm (EX-32.1) — 11KB
• cprx-ex32_2.htm (EX-32.2) — 11KB
• 0001193125-25-266854.txt ( ) — 11435KB
• cprx-20250930.xsd (EX-101.SCH) — 1366KB
• cprx-20250930_htm.xml (XML) — 2420KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS Consolidated balance sheets at September 30, 2025 (unaudited) and December 31, 2024 3 Consolidated statements of operations and comprehensive income for the three and nine months ended September 30, 2025 and 2024 (unaudited) 4 Consolidated statements of changes in stockholders' equity for the three and nine months ended September 30, 2025 and 2024 (unaudited) 5 Consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024 (unaudited) 7 Notes to unaudited consolidated financial statements 8 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 35 Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK 50 Item 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 50

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 51 Item 1A.

RISK FACTORS

RISK FACTORS 51 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 51 Item 3. DEFAULTS UPON SENIOR SECURITIES 52 Item 4. MINE SAFETY DISCLOSURE 52 Item 5. OTHER INFORMATION 52 Item 6. EXHIBITS 53

SIGNATURES

SIGNATURES 54 2 Table of Contents CATALYST PHARMACEUTICALS, INC. CONSOLIDATED BALA NCE SHEETS (in thousands, except share data) September 30, 2025 December 31, 2024 (unaudited) ASSETS Current Assets: Cash and cash equivalents $ 689,892 $ 517,553 Accounts receivable, net 106,409 65,476 Inventory, net 28,029 19,541 Prepaid expenses and other current assets 28,123 21,039 Total current assets 852,453 623,609 Operating lease right-of-use asset, net 2,010 2,230 Property and equipment, net 1,077 1,354 License and acquired intangibles, net 128,639 156,672 Deferred tax assets, net 48,256 45,982 Investment in equity securities 19,167 21,564 Total assets $ 1,051,602 $ 851,411 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 9,096 $ 16,593 Accrued expenses and other liabilities 119,639 104,085 Total current liabilities 128,735 120,678 Operating lease liability, net of current portion 2,461 2,786 Other non-current liabilities 161 315 Total liabilities 131,357 123,779 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.001 par value, 5,000,000 shares authorized: none issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 200,000,000 shares authorized; 123,264,583 shares and 120,879,099 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 123 121 Additional paid-in capital 473,333 442,286 Retained earnings 446,789 285,161 Accumulated other comprehensive income (loss) (Note 4) — 64 Total stockholders' equity 920,245 727,632 Total liabilities and stockholders' equity $ 1,051,602 $ 851,411 The accompanying notes are an integral part of these consolidated financial statements. 3 Table of Contents CATALYST PHARMACEUTICALS, INC. CONSOLIDATED STATEMEN